For these reasons we evaluated AR expression in UCM 1037-treated LNCaP and 22Rv1 cells and what we found was a remarkable down regulation of AR protein levels, which has never been observed before in melatonin-treated prostate cancer cells. The gene discussed is AR; the disease is prostate cancer.